Track topics on Twitter Track topics that are important to you
Netscientific PLC’s (LON:NSCI) portfolio company Glycotest has been granted a Japanese patent for its core technology for the early detection of life threatening liver disease. Glycotest – a liver disease diagnostics company – now holds a total of six patents in Australia, the US and Japan. The patents cover the use of over 50 unique glycoprotein biomarkers which can be used for the diagnosis of liver cancer and other liver diseases. "We are delighted that the Japanese patent can now be added to Glycotest's rising number of patents which add to the breadth of the IP for its liver disease diagnostic platform,” said NetScientific chief executive François Martelet. “These granted patents and additional pending applications put Glycotest in a strong position to further protect its proprietary technology as it continues to grow." Glycotest added that it expects to put out some more “good news” in the coming year with regards to its intellectual property position.
Original Article: NetScientific’s Glycotest secures Japanese patentNEXT ARTICLE
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...